Influence of Sociodemographic Variables on Patient and Practitioner Knowledge of Pharmacological Management Options for Parkinson's Disease: Research Article

Paula Abola; Kristin Lefebvre; Mitchell Wolden

doi:10.58372/2835-6276.1247

Authors

Paula Abola
Kristin Lefebvre
Mitchell Wolden

DOI:

https://doi.org/10.58372/2835-6276.1247

Abstract

Introduction: The pharmacological management of Parkinson's Disease (PD) is imperative to improve the quality of life for patients with the disease. However, the extent of knowledge among patients with PD and practitioners of pharmacological management options is unknown. Our primary aim was to investigate patient and practitioner knowledge of pharmacological management options for PD. Our secondary aim was to study the influence of sociodemographic variables on patient and practitioner knowledge of pharmacological management options for PD.

Methodology: The Knowledge Attitude Practice (KAP) model was adapted to develop a questionnaire that assesses patient and practitioner knowledge of pharmacological management options for PD. To determine the relationship between sociodemographic variables and patient and practitioner knowledge of pharmacological management options, basic frequency, likelihood-ratio chi-squared, Spearman's correlation, simple logistic regression, and multiple logistic regression analyses were performed.

Results: For patients (n = 492) and practitioners (n = 149), the most widely known pharmacological management option was Levodopa-Carbidopa immediate-release tablets, and the least-known was Procyclidine. Compared to patients, practitioners were more likely to have knowledge of most pharmacological management options (OR 1.62 - 9.38). Higher education level (OR 2.56 - 21.01), younger age (OR 0.17 - 0.32), geographical location (Europe OR 1.97 - 9.40, North America OR 0.07 - 0.44, Oceania OR 17.70 - 38.36), ethnicity (4.73 - 5.72), and employment status (OR 0.15 - 0.28) had a significant relationship with patient and practitioner knowledge of pharmacological management options.

Conclusion: Practitioners were more likely to have knowledge of most pharmacological management options for PD than patients. Sociodemographic variables such as education level, age, geographical location, ethnicity, and employment status influenced patient and practitioner knowledge of pharmacological management options.

References

Zafar S, Yaddanapudi SS. Parkinson Disease. PubMed. Published 2022. https://www.ncbi.nlm.nih.gov/books/NBK470193/#:~:text=Parkinson%20disease%20is%20a%20neurodegenerative

LeWitt PA, Chaudhuri KR. Unmet needs in Parkinson disease: Motor and non-motor. Parkinsonism & Related Disorders. 2020;80:S7-S12. doi:https://doi.org/10.1016/j.parkreldis.2020.09.024

Freitas ME, Hess CW, Fox SH. Motor Complications of Dopaminergic Medications in Parkinson’s Disease. Seminars in neurology. 2017;37(2):147-157. doi:https://doi.org/10.1055/s-0037-1602423

Ben-Joseph A, Marshall CR, Lees AJ, Noyce AJ. Ethnic Variation in the Manifestation of Parkinson’s Disease: A Narrative Review. Journal of Parkinson’s Disease. 2020;10(1):31-45. doi:https://doi.org/10.3233/jpd-191763

Reed X, Bandrés-Ciga S, Blauwendraat C, Cookson MR. The role of monogenic genes in idiopathic Parkinson’s disease. Neurobiology of Disease. 2019;124:230-239. doi:https://doi.org/10.1016/j.nbd.2018.11.012

Mollenhauer B, Zimmermann J, Sixel‐Döring F, et al. Baseline predictors for progression 4 years after Parkinson’s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Movement Disorders. 2018;34(1):67-77. doi:https://doi.org/10.1002/mds.27492

Morley JF, Xie SX, Hurtig HI, et al. Genetic influences on cognitive decline in Parkinson’s disease. Movement Disorders. 2012;27(4):512-518. doi:https://doi.org/10.1002/mds.24946

Pablo-Fernandez ED, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology. 2018;91(2):e139-e142. doi:https://doi.org/10.1212/WNL.0000000000005771

Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(10):2731-2742. doi:https://doi.org/10.1093/brain/awu195

Pan S, Stutzbach J, Reichwein S, Lee BK, Dahodwala N. Knowledge and Attitudes About Parkinson’s Disease Among a Diverse Group of Older Adults. Journal of Cross-Cultural Gerontology. 2014;29(3):339-352. doi:https://doi.org/10.1007/s10823-014-9233-x

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders. 2015;30(12):1591-1601. doi:https://doi.org/10.1002/mds.26424

Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. European Journal of Neurology. 2012;20(1):5-15. doi:https://doi.org/10.1111/j.1468-1331.2012.03866.x

Williams U, Bandmann O, Walker R. Parkinson’s Disease in Sub-Saharan Africa: A Review of Epidemiology, Genetics and Access to Care. Journal of Movement Disorders. 2018;11(2):53-64. doi:https://doi.org/10.14802/jmd.17028

Serper M, McCarthy DM, Patzer RE, et al. What patients think doctors know: Beliefs about provider knowledge as barriers to safe medication use. Patient Education and Counseling. 2013;93(2):306-311. doi:https://doi.org/10.1016/j.pec.2013.06.030

Arnetz JE, Almin I, Bergström K, Franzén Y, Nilsson H. Active patient involvement in the establishment of physical therapy goals: Effects on treatment outcome and quality of care. Advances in Physiotherapy. 2004;6(2):50-69. doi:https://doi.org/10.1080/14038190310017147

Salinas MR, Chambers EJ, Ho T, et al. Patient perceptions and knowledge of Parkinson’s disease and treatment (KnowPD). Clinical Parkinsonism & Related Disorders. 2020;3:100038. doi:https://doi.org/10.1016/j.prdoa.2020.100038

Galletta M, Piazza MF, Meloni SL, et al. Patient involvement in shared decision-making: Do patients rate physicians and nurses differently? International Journal of Environmental Research and Public Health. 2022;19(21). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656720/

Aishwaryalakshmi K, Sasikala B, Sreelalitha N, Vigneshwaran E, Padmanabha Y. Assessment of Knowledge Perception and Attitudes on Medications in General Population.; 2012. https://ijopp.org/sites/default/files/IJOPP_v5_i3_2012-16.pdf

Maher JM, Markey JC, Ebert-May D. The Other Half of the Story: Effect Size Analysis in Quantitative Research. CBE—Life Sciences Education. 2013;12(3):345-351. doi:https://doi.org/10.1187/cbe.13-04-0082

Zipprich HM, Mendorf S, Schönenberg A, Prell T. The impact of poor medication knowledge on health-related quality of life in people with Parkinson’s disease: a mediation analysis. Quality of Life Research. Published online November 19, 2021. doi:https://doi.org/10.1007/s11136-021-03024-8

Hoffmann R, Lutz SU. The health knowledge mechanism: evidence on the link between education and health lifestyle in the Philippines. The European Journal of Health Economics. 2018;20(1):27-43. doi:https://doi.org/10.1007/s10198-017-0950-2

Jansen T, Rademakers J, Waverijn G, Verheij R, Osborne R, Heijmans M. The role of health literacy in explaining the association between educational attainment and the use of out-of-hours primary care services in chronically ill people: a survey study. BMC Health Services Research. 2018;18(1). doi:https://doi.org/10.1186/s12913-018-3197-4

Alkatheri AM, Albekairy AM. Does the patients’ educational level and previous counseling affect their medication knowledge? Annals of Thoracic Medicine. 2013;8(2):105-108. doi:https://doi.org/10.4103/1817-1737.109823

O. Kaczmarek, A. Sethi, P. Tierney, B. Bumstead, M. Buhse, E. Kravis, B. Anand, M. Zarif, M. Gudesblatt. Parkinson’s Disease, Cognitive Function and Health Literacy: A Problem with Shared Decision Making [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/parkinsons-disease-cognitive-function-and-health-literacy-a-problem-with-shared-decision-making/

Gesundheit Österreich GmbH. HLS24 | M-POHL - WHO Action Network on Measuring Population and Organizational Health Literacy. M-pohl.net. Published 2024. https://m-pohl.net/HLS24

Tavousi M, Haeri-Mehrizi A, Rakhshani F, et al. Development and validation of a short and easy-to-use instrument for measuring health literacy: the Health Literacy Instrument for Adults (HELIA). BMC Public Health. 2020;20(1). doi:https://doi.org/10.1186/s12889-020-08787-2

Hsu WC. The Effect of Age on Electronic Health Literacy: Mixed-Method Study. JMIR Human Factors. 2019;6(2):e11480. doi:https://doi.org/10.2196/11480

Hermes-DeSantis ER, Hunter RT, Welch J, Bhavsar R, Boulos D, Noue MA. Preferences for Accessing Medical Information in the Digital Age: Health Care Professional Survey. Journal of medical Internet research. 2021;23(6):e25868. doi:https://doi.org/10.2196/25868

Hak DJ. Changing Nature of Continuing Medical Education. Orthopedics. 2013;36(10):748-748. doi:https://doi.org/10.3928/01477447-20130920-02

Busse R, Blümel M, Knieps F, Bärnighausen T. Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. The Lancet. 2017;390(10097):882-897. doi:https://doi.org/10.1016/s0140-6736(17)31280-1

V. Reggi, R. Balocco-Mattavelli, Bonati M, et al. Prescribing information in 26 countries: a comparative study. European journal of clinical pharmacology. 2003;59(4):263-270. doi:https://doi.org/10.1007/s00228-003-0607-1

Schuts EC, van Dulm E, Boyd A, et al. Knowledge and use of antibiotics in six ethnic groups: the HELIUS study. Antimicrobial Resistance & Infection Control. 2019;8(1). doi:https://doi.org/10.1186/s13756-019-0636-x

Schaafsma ES, Raynorr DK, de Jong‐van den Berg LTW. Accessing medication information by ethnic minorities: barriers and possible solutions. Pharmacy World and Science. 2003;25(5):185-190. doi:https://doi.org/10.1023/a:1025812716177

Nguyen A, Guttentag A, Li D, Meijgaard J van. The Impact of Job and Insurance Loss on Prescription Drug use: A Panel Data Approach to Quantifying the Health Consequences of Unemployment During the Covid-19 Pandemic. International Journal of Health Services. 2022;52(3):312-322. doi:https://doi.org/10.1177/00207314221078749

Åhs AMH, Westerling R. Health care utilization among persons who are unemployed or outside the labour force. Health Policy. 2006;78(2-3):178-193. doi:https://doi.org/10.1016/j.healthpol.2005.10.010

Saunders-Pullman R, Wang C, Stanley K, Bressman SB. Diagnosis and Referral Delay in Women With Parkinson’s Disease. Gender Medicine. 2011;8(3):209-217. doi:https://doi.org/10.1016/j.genm.2011.05.002

Pham-Duc P, Sriparamananthan K. Exploring gender differences in knowledge and practices related to antibiotic use in Southeast Asia: A scoping review. Clegg S, ed. PLOS ONE. 2021;16(10):e0259069. doi:https://doi.org/10.1371/journal.pone.0259069

Dawoodi I, Bhosale U. Evaluation of Knowledge and Awareness of Patients about Prescribed Drugs and their Package Inserts: A Cross-sectional Study. Asian Journal of Pharmaceutics. Published online May 3, 2016. https://www.academia.edu/64825563/Evaluation_of_Knowledge_and_Awareness_of_Patients_about_Prescribed_Drugs_and_their_Package_Inserts_A_Cross_sectional_Study?uc-g-sw=19754653

Daher M, Al Rifai M, Kherallah RY, et al. Gender disparities in difficulty accessing healthcare and cost-related medication non-adherence: The CDC behavioral risk factor surveillance system (BRFSS) survey. Preventive Medicine. 2021;153:106779. doi:https://doi.org/10.1016/j.ypmed.2021.106779

Mann G, Rizvi F, Rovner G. Extended Release Carbidopa-Levodopa vs Immediate Release Carbidopa-Levodopa in Treating Parkinson’s Disease Acknowledgments. https://www.csuohio.edu/sites/default/files/%2831%29%20Extended%20Release%20Carbidopa-Levodopa%20vs%20Immediate%20Release.pdf

Kuntz JL, Safford MM, Singh JA, et al. Patient-centered interventions to improve medication management and adherence: A qualitative review of research findings. Patient Education and Counseling. 2014;97(3):310-326. doi:https://doi.org/10.1016/j.pec.2014.08.021

Suttrup I, Warnecke T. Dysphagia in Parkinson’s Disease. Dysphagia. 2015;31(1):24-32. doi:https://doi.org/10.1007/s00455-015-9671-9

Buhmann C, Bihler M, Emich K, et al. Pill swallowing in Parkinson’s disease: A prospective study based on flexible endoscopic evaluation of swallowing. Parkinsonism & Related Disorders. 2019;62:51-56. doi:https://doi.org/10.1016/j.parkreldis.2019.02.002

Güneş M, Karavana Sy. Non-oral Drug Delivery in Parkinson’s Disease: Current Applications and Future. Turkish Journal of Pharmaceutical Sciences. 2021;0(0). doi:https://doi.org/10.4274/tjps.galenos.2021.95226

van Halteren AD, Munneke M, Smit E, Thomas S, Bloem BR, Darweesh SKL. Personalized Care Management for Persons with Parkinson’s Disease. Bloem BR, Brundin P, eds. Journal of Parkinson’s Disease. 2020;10(s1):S11-S20. doi:https://doi.org/10.3233/jpd-202126